Top Buy Stocks
Sign In
Invest in CDTX
Cidara Therapeutics Earnings Calls
| Release date | May 08, 2025 |
| EPS estimate | -$5.45 |
| EPS actual | -$1.66 |
| EPS Surprise | 69.54% |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Mar 06, 2025 |
| EPS estimate | -$5.28 |
| EPS actual | -$5.38 |
| EPS Surprise | -1.89% |
| Revenue estimate | 240K |
| Revenue actual | - |
| Release date | Nov 07, 2024 |
| EPS estimate | -$5.22 |
| EPS actual | -$2.38 |
| EPS Surprise | 54.41% |
| Revenue estimate | 400K |
| Revenue actual | - |
| Release date | Aug 13, 2024 |
| EPS estimate | -$3.94 |
| EPS actual | -$2.05 |
| EPS Surprise | 47.97% |
| Revenue estimate | 4.7M |
| Revenue actual | 302K |
| Revenue Surprise | -93.57% |
Last 4 Quarters for Cidara Therapeutics
Below you can see how CDTX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $12.15 |
| EPS estimate | -$3.94 |
| EPS actual | -$2.05 |
| EPS surprise | 47.97% |
| Date | Price |
|---|---|
| Aug 07, 2024 | $11.29 |
| Aug 08, 2024 | $11.59 |
| Aug 09, 2024 | $11.81 |
| Aug 12, 2024 | $11.73 |
| Aug 13, 2024 | $12.15 |
| Aug 14, 2024 | $12.86 |
| Aug 15, 2024 | $12.64 |
| Aug 16, 2024 | $12.79 |
| Aug 19, 2024 | $12.96 |
| 4 days before | 7.62% |
| 4 days after | 6.67% |
| On release day | 5.84% |
| Change in period | 14.79% |
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $13.11 |
| EPS estimate | -$5.22 |
| EPS actual | -$2.38 |
| EPS surprise | 54.41% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $13.09 |
| Nov 04, 2024 | $13.03 |
| Nov 05, 2024 | $13.26 |
| Nov 06, 2024 | $13.26 |
| Nov 07, 2024 | $13.11 |
| Nov 08, 2024 | $13.50 |
| Nov 11, 2024 | $13.35 |
| Nov 12, 2024 | $13.45 |
| Nov 13, 2024 | $13.90 |
| 4 days before | 0.153% |
| 4 days after | 6.03% |
| On release day | 2.97% |
| Change in period | 6.19% |
| Release date | Mar 06, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $23.61 |
| EPS estimate | -$5.28 |
| EPS actual | -$5.38 |
| EPS surprise | -1.89% |
| Date | Price |
|---|---|
| Feb 28, 2025 | $24.90 |
| Mar 03, 2025 | $23.05 |
| Mar 04, 2025 | $23.16 |
| Mar 05, 2025 | $23.50 |
| Mar 06, 2025 | $23.61 |
| Mar 07, 2025 | $23.66 |
| Mar 10, 2025 | $22.39 |
| Mar 11, 2025 | $21.00 |
| Mar 12, 2025 | $23.00 |
| 4 days before | -5.18% |
| 4 days after | -2.58% |
| On release day | 0.212% |
| Change in period | -7.63% |
| Release date | May 08, 2025 |
| Fiscal end date | Mar 31, 2025 |
| Price on release | $19.15 |
| EPS estimate | -$5.45 |
| EPS actual | -$1.66 |
| EPS surprise | 69.54% |
| Date | Price |
|---|---|
| May 02, 2025 | $21.69 |
| May 05, 2025 | $21.50 |
| May 06, 2025 | $19.70 |
| May 07, 2025 | $18.98 |
| May 08, 2025 | $19.15 |
| May 09, 2025 | $18.63 |
| May 12, 2025 | $19.43 |
| May 13, 2025 | $19.36 |
| May 14, 2025 | $19.31 |
| 4 days before | -11.71% |
| 4 days after | 0.81% |
| On release day | -2.72% |
| Change in period | -11.00% |
Cidara Therapeutics Earnings Call Transcript Summary of Q1 2025
Summary of Cidara Therapeutics Q1 2025 Earnings Call
Here's a summary of the key points from the Cidara Therapeutics Q1 2025 earnings call that investors should know:
- Introduction of CD388
Cidara's lead asset, CD388, is a novel antiviral drug for the prevention of influenza, designed to have universal activity against all strains, including high pathogenicity strains like H5N1. CD388 combines the antiviral zanamivir with a human antibody fragment to enhance efficacy and prolong its half-life, allowing for potentially once-per-season dosing.
- Clinical Trial Updates
The NAVIGATE Phase 2b study, which evaluates CD388 across three dosage groups (150 mg, 300 mg, and 450 mg) versus a placebo in 5,041 subjects, has completed dosing. Primary analysis results are expected to be announced by June 2025. Discussions with the FDA regarding the possibility of evaluating statistical significance in the study are ongoing due to the severity of the 2025 flu season.
- Target Population Focus
The initial target for CD388 is high-risk, comorbid, and immune-compromised patients, who are disproportionately affected by influenza. This population has significantly higher hospitalization and death rates and is under-served by existing treatments.
- Market Opportunity and Pricing
While historical estimates suggest a potential addressable market of around 20 million patients, the company sees opportunities to broaden this scope beyond severely affected individuals to include those with moderate conditions. Pricing discussions indicate potential for a value-based pricing approach substantially above previously modeled figures of $180-$200.
- R&D Day on May 22
A detailed R&D Day is scheduled for May 22, 2025, where more information on the ongoing clinical trials, data, regulatory discussions, and market needs will be shared.
- Complementarity with Vaccines
CD388 acts on a different target (neuraminidase) than traditional vaccines (which target hemagglutinin), implying potential complementarity rather than direct competition, especially in patients who are not adequately protected by vaccines.
- Forward-Looking Statements
As a non-revenue-generating company, Cidara cautions investors about forward-looking statements and uncertainties that may affect future results and timelines.
Overall, investors should monitor the upcoming results from the NAVIGATE study and insights from the R&D day for indications of CD388's market potential and regulatory path forward.
